---
title: Improve sleep with bright light
nct_id: NCT06129942
phase: NA
status: RECRUITING
sponsor: Second Affiliated Hospital of Soochow University
study_type: INTERVENTIONAL
canonical_url: "https://parkinsonspathways.com/trial/NCT06129942"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT06129942"
last_fetched: "2026-05-10T14:05:42.016Z"
source: "Parkinson's Pathways (curated)"
---
# Improve sleep with bright light

**Goal (in five words):** Improve sleep with bright light

**Official Title:** Light Therapy in Parkinson's Disease: a Prospective, Observational Study

**Trial ID:** [NCT06129942](https://clinicaltrials.gov/study/NCT06129942)

## Key Facts

- **Phase:** NA
- **Status:** RECRUITING
- **Study Type:** INTERVENTIONAL
- **Sponsor:** Second Affiliated Hospital of Soochow University
- **Target Enrollment:** 50 participants
- **Start Date:** 2021-09-01
- **Completion Date:** 2026-05-16
- **Conditions:** Parkinson Disease, Sleep Disorder, Circadian Rhythm Disorders
- **Interventions:** Bright light box, Dim Light box
- **Intervention Types:** DEVICE

## Summary For Families

The trial is testing whether daily light therapy can improve sleep and circadian rhythm problems in people with moderate Parkinson's, with the goal of improving nighttime sleep, daytime alertness, and overall function. Participants use either a bright light box or a dim light box as a control, with light exposure stimulating the retina to reset the brain's circadian clock and boost wakefulness; it does not directly change how levodopa works, and everyone keeps their Parkinson's medications stable during the study. They are looking for people aged 50 to 80 with Parkinson's at Hoehn and Yahr stages 2 to 3 who have had stable Parkinson's meds for at least one month and agree not to change them. People with major visual problems, significant cognitive impairment (MMSE under 24), uncontrolled psychiatric symptoms, current use of hypnotics or stimulants, or major circadian disruptions like shift work or recent jet lag are excluded; antidepressants are allowed only if the dose has been stable for more than three months.

## Eligibility

- **Minimum age:** 50 Years
- **Maximum age:** 80 Years
- **Sex:** ALL

### Full Criteria

```
Inclusion Criteria:

* According to the criteria of PD diagnosis of the MDS, PD patients were selected as the research object. The clinical symptoms of PD patients were consistent with Hoehn and Yahr stages 2-3.
* All PD patients have maintained stable drug treatment for at least one month, signed clinical informed consent and agreed not to adjust drugs throughout the light test and follow-up period.

Exclusion Criteria:

* Using hypnotic or stimulating drugs.
* Using antidepressants, except stable drugs maintained for more than three months;
* Visual impairment, such as cataract, glaucoma, blindness, etc;
* Cognitive impairment (MMSE \< 24);
* There are uncontrollable hallucinations and mental diseases;
* There are sleep phase delay / advance syndrome, shift work, jet lag, etc
```

## Locations (1)

- Department of Neurology, Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China _(31.3041, 120.5954)_
  - Chun-Feng Liu, Ph.D, M.D. — (CONTACT) — 00 86 512 67783307 — liuchunfeng@suda.edu.cn
  - Chun-Feng Liu, Ph.D,M.D. — (PRINCIPAL_INVESTIGATOR)

## Central Contacts

- Chun-Feng Liu, PhD — (CONTACT) — +86 512 67783307 — liuchunfeng@suda.edu.cn

---

*Canonical: https://parkinsonspathways.com/trial/NCT06129942*  
*HTML version: https://parkinsonspathways.com/trial/NCT06129942*  
*Source data: https://clinicaltrials.gov/study/NCT06129942*